Related Experiment Video
Updated: Jul 1, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study
Helena Iznardo1, Esther Roé1, Asunción Vicente2
1Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IR SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Spain.
Insights
Dupilumab effectively treats moderate-to-severe atopic dermatitis (AD) in children, showing significant symptom improvement and high treatment adherence in a Spanish real-world study. The drug demonstrated a good safety profile with manageable adverse events.
Area of Science:
- Dermatology
- Paediatric Medicine
- Pharmacology
Background:
- Moderate-to-severe atopic dermatitis (AD) presents significant management challenges in paediatric populations.
- Limited licensed treatment options exist for children with AD.
- Dupilumab is an approved biologic therapy for AD in children over six months of age.
Purpose of the Study:
- To evaluate the real-world effectiveness and safety of dupilumab in paediatric patients with moderate-to-severe AD in Spain.
- To assess treatment outcomes including symptom severity, quality of life, and drug survival.
Main Methods:
- A multicentre, retrospective real-world study was conducted.
- Involved 243 patients aged 2-18 years with moderate-to-severe AD.
- Assessed effectiveness using Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI), and Numerical Rating Scale (NRS) for itch. Safety and drug survival were also evaluated.
Main Results:
- Dupilumab showed significant effectiveness, with substantial reductions in AD severity scores observed from week 4.
- By week 52, 85.8% of patients achieved EASI 75 and 49.6% achieved EASI 90.
- Adverse events (AEs) were reported in 17.7% of patients, most commonly ocular surface disease (8.2%). Drug survival rates were high at 96.9% and 93.1% after 1 and 2 years, respectively.
Conclusions:
- Real-world data confirm dupilumab's sustained effectiveness and acceptable safety profile in paediatric patients with moderate-to-severe AD.
- High drug survival rates indicate good tolerability and patient adherence.
- Further long-term studies are recommended for comprehensive adverse event surveillance and management of disease remission.
Background:
Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, and there are few licensed treatments available for this age group. Dupilumab is approved for the treatment of AD in children older than 6 months.
Objectives:
To assess the effectiveness and safety of dupilumab in a real-world cohort of paediatric patients with AD in Spain.
Methods:
A multicentre, retrospective real-world study on the effectiveness and safety of dupilumab in patients aged 2-18 years with moderate-to-severe AD was conducted. Demographic and clinical characteristics were analysed, and effectiveness (Eczema Area and Severity Index, Investigator's Global Assessment, Dermatology Life Quality Index, Numerical Rating Scale itch), safety and drug survival measures were assessed. A comparison of our results with other real-world outcomes and with clinical trials was made.
Results:
Data from 243 patients from 19 centres were collected, with a mean follow-up of 85 weeks. Dupilumab exhibited significant effectiveness, with marked reductions in severity scores from week 4. By week 16, 79.4% of patients achieved ≥ 75% improvement in Eczema Area and Severity Index (EASI) score (EASI 75) and 40.5% achieved ≥ 90% improvement in EASI score (EASI 90). Mean percentage reduction in EASI was 79.7%. Increasing improvements were observed until week 52, with 85.8% and 49.6% of patients achieving EASI 75 and EASI 90, respectively. Forty-three patients developed adverse events (AEs) (43 of 243, 17.7%). The most frequent AEs were ocular surface diseases (20 of 243, 8.2%), injection site reactions (8 of 243, 3.3%) and facial redness (7 of 243, 2.9%). Drug survival was high (96.9% and 93.1% after 1 and 2 years of follow-up, respectively), with only 19 patients (7.8%) interrupting treatment: 7 (2.9%) owing to AEs; 2 (0.82%) owing to secondary failure; 5 (2.1%) were lost to follow-up; and 5 (2.1%) entered remission and stopped treatment.
Conclusions:
Real-world use of dupilumab in paediatric AD demonstrated sustained effectiveness, high drug survival and acceptable safety profiles. Longer-term studies are crucial for AE surveillance and understanding how to manage disease remission.
More Related Videos
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion